BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Get Rating) Director Machelle Sanders sold 4,000 shares of the business’s stock in a transaction dated Thursday, June 15th. The shares were sold at an average price of $7.98, for a total value of $31,920.00. Following the sale, the director now owns 25,611 shares in the company, valued at approximately […]
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Get Rating) was the target of a large increase in short interest in May. As of May 31st, there was short interest totalling 35,580,000 shares, an increase of 10.2% from the May 15th total of 32,300,000 shares. Based on an average daily trading volume, of 2,730,000 shares, the days-to-cover ratio […]
Victory Capital Management Inc. lowered its stake in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Get Rating) by 28.0% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,533,398 shares of the biotechnology company’s stock after selling 986,833 shares during the quarter. […]
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Get Rating) – Stock analysts at HC Wainwright decreased their FY2027 earnings per share estimates for BioCryst Pharmaceuticals in a research note issued on Thursday, May 4th. HC Wainwright analyst A. Fein now expects that the biotechnology company will post earnings of $1.16 per share for the year, down from […]
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Get Rating) has received an average recommendation of “Moderate Buy” from the eleven analysts that are presently covering the firm, MarketBeat.com reports. Four research analysts have rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average 12-month price objective among brokerages […]